Canada's Virogin raises $120m led by China Life; to use proceeds for Shanghai R&D centre

Canada's Virogin raises $120m led by China Life; to use proceeds for Shanghai R&D centre

Virogin Biotech, a Vancouver, Canada-based developer of next-generation oncolytic virus (OV) therapeutics, has raised over $120 million in a Series D2 round of financing as the company looks to build its global R&D centre in China’s Shanghai city.

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief
Subscribe to Newsletter